Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Reuters NEXT Gulf leadership summit to return with Abu Dhabi Department of Economic Development as exclusive host city partner for next three years

    August 21, 2026

    Thumbay International Pathway – MD Program, With Installments and a Direct Route to Residency in Romania

    August 21, 2026

    STARTRADER Launches XAUUSD247, Extending Gold CFD Access Across the Full Week

    August 21, 2026
    Facebook X (Twitter) Instagram
    Arab BulletinArab Bulletin
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Arab BulletinArab Bulletin
    Home » Innovative experimental malaria drug based on antibodies discovered
    Featured News

    Innovative experimental malaria drug based on antibodies discovered

    November 1, 2022
    Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    A new study in Africa has found that a one-time dose of an experimental drug protects adults against malaria for at least six months. In 2020, malaria killed more than 620,000 people and sickened 241 million, mostly children under 5. There is a malaria vaccine being rolled out by the World Health Organization for children, but it is only 30% effective and requires four doses.

    Innovative experimental malaria drug based on antibodies discoveredIn this new study, people received a large dose of lab-made malaria-fighting antibodies instead of relying on the immune system to make enough of those same infection-blockers after vaccination, reported the Associated Press (AP). “There are not enough people protected by the vaccine available,” said Kassoum Kayentao, a researcher from the University of Sciences, Techniques and Technologies in Bamako, Mali.

    In those villages, people are bitten by infected mosquitoes on average twice a day during malaria season, according to other research. Experimental antibody, developed by researchers at the US National Institutes of Health, was delivered by IV. In the meantime, an easy-to-administer shot version from the same scientists is in early testing in infants, children, and adults.

    Research presented at a medical meeting in Seattle was published Monday in the New England Journal of Medicine. In order to work, the antibody breaks the life cycle of the parasite, which is spread through mosquito bites. It targets immature parasites before they mature and multiply in the liver. An antibody taken from a volunteer who received a malaria vaccine was used to develop it.

    It involved 330 adults in Mali who received either a dummy infusion or two different antibody doses. Every two weeks for 24 weeks, all were tested for malaria infection. Treatment was provided to anyone who became ill. A blood test detected infections in 20 people who received the higher dose, 39 people who received the lower dose, and 86 people who received the placebo. Compared to the placebo, the higher dose was 88% effective. There was a 75% effectiveness rate for the lower dose.

    During a malaria season, protection might last for several months. In the future, it could be used in conjunction with other malaria prevention methods, such as malaria pills, mosquito nets, and vaccinations. According to one estimate, lab-made antibodies could be given for as little as $5 per child per malaria season.

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email

    Related Posts

    Featured News August 21, 2026

    Thumbay International Pathway – MD Program, With Installments and a Direct Route to Residency in Romania

    Featured News August 19, 2026

    SOUEAST UAE launches S08 Luxury following the success of the Flagship S08DM

    Featured News August 18, 2026

    Thumbay Group and UMFST G.E. Palade Targu Mures, Romania Launch Thumbay – UMFST International Residency Pathway Program, Opening the Door to 49 European Medical Specialties

    PR Newswire August 13, 2026

    LG INSTAVIEW™ REFRIGERATOR SURPASSES 5.3 MILLION IN GLOBAL SALES

    Featured News August 9, 2026

    KoçSistem Leads Türkiye’s IT System Integrator for the Eighth Consecutive Year as KoçDigital Wins Top AI Award

    Featured News August 7, 2026

    Papa Johns teams up with Disney and Pixar for Toy Story 5

    Latest News
    Business August 20, 2026

    Wall Street rises after Treasury expands debt buybacks

    Healthcare shares strengthen market gains
    Healthcare stocks provided another source of support during Wednesday’s session as several pharmaceutical shares recorded large gains. Moderna shares surged 177%, while Merck advanced 12.6% after the companies announced positive results from a Phase 3 melanoma trial. The INTerpath-001 study tested personalized mRNA therapy intismeran autogene with Keytruda following surgical removal of high-risk melanoma. The combination met its primary endpoint for recurrence-free survival. It also met a key secondary endpoint measuring survival without distant cancer spread.

    WHO maps three-month path for Congo Ebola containment

    August 19, 2026

    Indonesia 6.1 earthquake rattles North Sumatra coast

    August 19, 2026

    DRC malaria cases surpass 26 million in 2025

    August 17, 2026

    DRC Ebola outbreak sets national death toll record

    August 17, 2026

    South Korea auto exports reach $6.24 billion in July

    August 14, 2026
    © 2026 Arab Bulletin | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.